CN101306011A - Function food for synthetically reducing blood pressure - Google Patents
Function food for synthetically reducing blood pressure Download PDFInfo
- Publication number
- CN101306011A CN101306011A CNA2008100286200A CN200810028620A CN101306011A CN 101306011 A CN101306011 A CN 101306011A CN A2008100286200 A CNA2008100286200 A CN A2008100286200A CN 200810028620 A CN200810028620 A CN 200810028620A CN 101306011 A CN101306011 A CN 101306011A
- Authority
- CN
- China
- Prior art keywords
- potassium
- blood pressure
- functional food
- alginate
- taurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a functional food used for lowering blood pressure in a combined manner. The functional food comprises the active ingredients by the weight percentages as follows: 5 to 70 percent of alginate, 5 to 70 percent of nutrient potassium, 10 to 75 percent of taurine and 15 to 80 percent of L-arginine. In the active ingredients of the functional food, the alginate has the function of removing sodium, the nutrient potassium can supplement the normal potassium contents in human bodies, the taurine can effectively regulate the contents of potassium, calcium and sodium in vivo so as to avoid the losses of potassium and sodium, and the L-arginine has the functions of relaxing the blood vessels and increasing the blood flow volume. The functional food combines the functions of the alginate, the nutrient potassium, the taurine and the L-arginine according to a certain rule, and manufactures the functional food according to a certain component proportion, thereby leading the alginate, the nutrient potassium, the taurine and the L-arginine to be put into full-play during the process of lowering the blood pressure, and achieving the purpose of effectively lowering the blood pressure.
Description
Technical field
The present invention relates to a kind of functional food that is used for blood pressure lowering, relating in particular to a kind of is the functional food that is used for blood pressure lowering of feedstock production with aminoacid, trace element and Sargassum extract.
Background technology
Hypertension is a kind of global commonly encountered diseases, and prevalence is up to 10-20%, and causes diseases such as cerebrovascular, heart and brain and kidney, is the principal disease of harm humans health.At present China has the hyperpietic nearly 1.5 hundred million approximately, and these data also increase continuing.Though the progress of science and the development of medicine and pharmacology, the doctor can suffer from hypertensive number and rise constantly for the hypertensive patient provides new types of drugs, suffer from hypertensive crowd and enlarging, and the existing tangible ascendant trend of the teenager ratio among the patient.Hypertension is not only given individual, family's Jonah and heavy financial burden, but also brings heavy burden on societys such as medical insurance to country.
At present, most of hyperpietics mainly are by Drug therapy.Traditional drug therapy is blood pressure lowering effectively, but all there is the problem of toxic and side effects in medicine, and these toxic and side effects not only reduce hyperpietic's quality of life, and increases the weight of the infringement to liver, renal function, reduces life-span.So the hyperpietic does not really break away from the threat of diseases such as cerebral hemorrhage that hypertension causes, cardiac sudden death in the traditional treatment process of taking medicine, taking medicine all the life everyday.Because 90% above hypertension pathogeny is not clear, so still difficult at present radical cure but can control, prevention ahead of time and effectively control hypertensive development is the effective way of aided blood pressure-lowering.
At present domestic functional food with blood pressure lowering is few, the functional food of some blood pressure lowering mainly is that to select the Chinese herbal medicine of medicine-food two-purpose for use with reference to Chinese medicine blood pressure lowering mechanism be that raw material prepares, with aminoacid, trace element and Sargassum extract is raw material, comes the functional food of synthetically reducing blood pressure not see as yet from many aspects.
Summary of the invention
The object of the present invention is to provide a kind of functional food that is used for synthetically reducing blood pressure, this functional food blood pressure lowering effective component is clear and definite, and steady quality has no side effect.
Solution of the present invention is based on understanding that forms hypertensive mechanism and synthetically reducing blood pressure and principle, and to the understanding of the mechanism of action of employing raw material, with reference to modern medicine and pharmacological research achievement, with aminoacid, trace element and Sargassum extract is primary raw material, scientific composition, make its performance kalium replenishment row sodium, regulate various trace elements such as sodium, potassium, calcium balance in vivo, the effect of expansion vascular flow amount, play the effect of synthetically reducing blood pressure.
Active component and the weight content thereof of forming functional food of the present invention are:
Alginate 5～70%
Nutrition potassium 5～70%
Taurine 10～75%
L-arginine 15～80%.
The preferred weight content of forming the active component of functional food of the present invention is:
Alginate 10～40%
Nutrition potassium 15～45%
Taurine 20～50%
L-arginase 12 5～55%.
In the above-mentioned active component, described alginate is meant employed alginic acid zinc, calcium alginate, sodium alginate, potassium alginate or alginic acid magnesium in drug additive, food additive and health food nutrient; Described nutrition potassium is meant employed potassium carbonate, dipotassium hydrogen phosphate, potassium chloride, potassium citrate, potassium gluconate, potassium lactate, potassium sulfate or potassium glycerinophosphate in drug additive, food additive and health food nutrient; Described taurine is meant the taurine that extracts or the taurine of synthetic from biology.
The above-mentioned functional food that is used for synthetically reducing blood pressure by common process, can be made said multiple dosage form on the pharmaceutics, as capsule, tablet, powder, electuary, unguentum or granule.
An important feature of the present invention is the mechanism of action of alginate row sodium.Low salt diet is one of Primary Care method of hyperpietic, can improve the antihypertensive effect of antihypertensive drug, the side effect that reduces the antihypertensive drugs consumption and may occur.Concerning slight or early high blood pressure, limit salt can make blood pressure recover normal merely.The low potassium of high sodium in hyperpietic's blood is a basic feature, alginate forms alginic acid and corresponding cation under the effect of gastric acid, alginic acid enters in the body in the back, and the carboxyl of alginic acid combines and excretes with sodium in the Sal, to reach the effect of arranging sodium.
Another important feature supplementation of taurine of the present invention; taurine is the koinomatter of body; be the metabolite of normal sulfur-containing amino acid in the body, it can be to sodium, potassium; various trace elements such as calcium play regulating action; when intravital sodium content was high, taurine can promote potassium, the affinity of calcium and sodium; sodium is by potassium, and calcium is replaced and descended.When sodium content in the body is low, potassium, the affinity of calcium and sodium descends, and can avoid potassium, the loss of calcium, salt sensitivity hypertension has antihypertensive effect preferably.
Another characteristics of the present invention are mechanism of action that the L-arginine improves blood vessel.The L-arginine is the synthetic nitric oxide production precursor of blood vessel endothelium, synthetic endogenous nitric oxide under the effect of nitric oxide synthetase.Nitric oxide has lax vascular smooth muscle, and vasodilator is regulated Peripheral resistance and other biological effect.The patients with hypertension arteriole attenuates, the visible ischemic region of 61.7% patient, show the arteriole spasm, narrow and inaccessible be the main pathological change of hypertension, because Microvascular rarefaction and arteriole attenuate, must cause Peripheral resistance significantly to increase, hypertensive generation development is produced material impact.The L-arginine can increase the effect that the partial blood flow of ischemia cortex produces blood pressure lowering by blood capillary, the microcirculation improvement of expansion patients with hypertension.
Nutrition potassium is as the supplement of potassium ion, to improve the normal potassium content of human body.
Hypertension is that multiple factor causes, and the present invention is that the wherein main pathogeny of basis adopts multiple function raw material to carry out the science compatibility.Alginate has the effect of row's sodium; Nutrition potassium can replenish the normal potassium content of human body; Taurine can effectively be regulated potassium, and calcium, sodium content in vivo can be avoided potassium, the loss of calcium; L-arginine vasodilator, the function of blood flow increasing is made up the effect that they can play by certain law, and by certain component proportion, make functional food, make four kinds of raw materials in the process of synthetically reducing blood pressure, give full play to each self-applying, to reach the purpose of effective blood pressure lowering.The present invention proves to have the function of obvious blood pressure lowering through the animal function test.
In addition, functional food effective component of the present invention is clear and definite, and steady quality is easy to control.The raw material components that the present invention selects for use is few, flat flavor, and instant has no side effect.
The present invention is further illustrated below in conjunction with the specific embodiment and contractile studies.
The specific embodiment
The present invention will be described below to enumerate specific embodiment.It is pointed out that embodiment only is used for that the invention will be further described, do not represent protection scope of the present invention, nonessential modification and adjustment that other people prompting according to the present invention is made still belong to protection scope of the present invention.
Embodiment 1
Active component and the weight content thereof of forming functional food of the present invention are:
Potassium alginate 60%
Potassium citrate 15%
Taurine 10%
L-arginine 15%.
Embodiment 2
Active component and the weight content thereof of forming functional food of the present invention are:
Sodium alginate 50%
Dipotassium hydrogen phosphate 20%
Taurine 10%
L-arginase 12 0%.
Embodiment 3
Active component and the weight content thereof of forming functional food of the present invention are:
Calcium alginate 30%
Potassium lactate 30%
Taurine 20%
L-arginase 12 0%.
Embodiment 4
Active component and the weight content thereof of forming functional food of the present invention are:
Alginic acid zinc 15%
Potassium glycerinophosphate 15%
Taurine 35%
L-arginine 35%.
Embodiment 5
Active component and the weight content thereof of forming functional food of the present invention are:
Alginic acid magnesium 30%
Potassium carbonate 25%
Taurine 20%
L-arginase 12 5%.
The functional food that is used for synthetically reducing blood pressure of the foregoing description by common process, can be made said multiple dosage form on the pharmaceutics, as capsule, tablet, powder, electuary, unguentum or granule.
The animal function test
The capsule that employing the foregoing description 1 prescription is made carries out animal function test, date processing, result's judgement according to Ministry of Public Health " health food check and assessment technique standard (2003 editions) " regulation.
1 test:
1.1 capsule of the present invention is to the influence of rat body weight
What table 1 was respectively organized rat is tried (the x ± SD) of body weight before and after the thing
By table 1 as seen, relatively, there are no significant for difference (P＞0.05) between each dosage group and 0g/kgBW group for the initial body weight of rat.The initial body weight that is rat is comparatively balanced between each group.Per os gives the capsule of the present invention of rat various dose after 4 weeks, and relatively, there are no significant for difference (P＞0.05) between each dosage group and 0g/kgBW group for rat body weight.Being capsule of the present invention has no adverse effects to the body weight of rat.
1.2 capsule of the present invention is to the influence of spontaneous hypertension rat blood pressure
Table 2 capsule of the present invention is to the influence of spontaneous hypertension rat blood pressure (unit: the mmHg of x ± SD)
*: relatively there were significant differences with the 0g/kgBW group
By table 2 as seen, per os gives the 4th week of capsule of the present invention of spontaneous hypertension rat various dose, compares with the 0g/kgBW group, and this is tried thing can significantly reduce spontaneous hypertension rat blood pressure (P＜0.01) in the 0.38g/kgBW group; Can significantly reduce spontaneous hypertension rat blood pressure (P＜0.05) in the 0.75g/kgBW group.
1.3 capsule of the present invention is to the influence of spontaneous hypertension rat heart rate
Table 3 capsule of the present invention is to the influence of the spontaneous hypertension rat heart rate (unit of x ± SD): inferior/min
By table 3 as seen, per os gives the capsule of the present invention of spontaneous hypertension rat various dose, is tried thing 1-4 week and stop to be tried the rat heart rate in 1 week of thing to compare between each dosage group and 0g/kgBW group, and there are no significant for difference (P＞0.05).Being capsule of the present invention has no adverse effects to the heart rate of spontaneous hypertension rat.1.4 capsule of the present invention is to the influence of normal animal groups rat blood pressure and heart rate
Table 4 capsule of the present invention to the influence of normal animal groups rat blood pressure and heart rate (x ± SD, n=10)
By table 4 as seen, per os gives the capsule of the present invention that the intact animal organizes rat 0.75g/kgBW, is tried thing 1-4 week and stops to be tried the rat blood pressure and the heart rate in 1 week of thing and tried comparison before the thing, and there are no significant for difference (P＞0.05).Being capsule of the present invention has no adverse effects to blood pressure and the heart rate of normal animal groups rat.
2. result
Per os gives the 4th week of capsule of the present invention of spontaneous hypertension rat various dose, compares with the 0g/kgBW group, and this is tried thing can significantly reduce spontaneous hypertension rat blood pressure (P＜0.01) in the 0.38g/kgBW group; Can significantly reduce spontaneous hypertension rat blood pressure (P＜0.05) in the 0.75g/kgBW group.Growth has no adverse effects to rat body weight to be tried thing; Blood pressure and the heart rate of each dosage group spontaneous hypertension rat heart rate and intact animal being organized rat all do not have influence.Criterion according to Ministry of Public Health " health food check and assessment technique standard (2003 editions) " judges that capsule of the present invention has the effect of aided blood pressure-lowering.
Claims (6)
1, a kind of functional food that is used for synthetically reducing blood pressure is characterized in that active component and the weight content thereof of forming this functional food are:
Alginate 5～70%
Nutrition potassium 5～70%
Taurine 10～75%
L-arginine 15～80%.
2, the functional food that is used for synthetically reducing blood pressure according to claim 1 is characterized in that the weight content of each active component is:
Alginate 10～40%
Nutrition potassium 15～45%
Taurine 20～50%
L-arginase 12 5～55%.
3, the functional food that is used for synthetically reducing blood pressure according to claim 1 and 2 is characterized in that described alginate is meant employed alginic acid zinc, calcium alginate, sodium alginate, potassium alginate or alginic acid magnesium in drug additive, food additive and health food nutrient.
4, the functional food that is used for synthetically reducing blood pressure according to claim 1 and 2 is characterized in that described nutrition potassium is meant employed potassium carbonate, dipotassium hydrogen phosphate, potassium chloride, potassium citrate, potassium gluconate, potassium lactate, potassium sulfate or potassium glycerinophosphate in drug additive, food additive and health food nutrient.
5, the functional food that is used for synthetically reducing blood pressure according to claim 1 and 2 is characterized in that described taurine is meant the taurine that extracts or the taurine of synthetic from biology.
6, the functional food that is used for synthetically reducing blood pressure according to claim 1 and 2, the dosage form that it is characterized in that described functional food is capsule, tablet, powder, electuary, unguentum or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100286200A CN101306011B (en) | 2008-06-06 | 2008-06-06 | Function food for synthetically reducing blood pressure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100286200A CN101306011B (en) | 2008-06-06 | 2008-06-06 | Function food for synthetically reducing blood pressure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101306011A true CN101306011A (en) | 2008-11-19 |
| CN101306011B CN101306011B (en) | 2011-11-30 |
Family
ID=40122847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100286200A Expired - Fee Related CN101306011B (en) | 2008-06-06 | 2008-06-06 | Function food for synthetically reducing blood pressure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101306011B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283338B2 (en) | 2007-11-30 | 2012-10-09 | Kao Corporation | GIP secretion inhibitor |
| US8338389B2 (en) | 2009-06-17 | 2012-12-25 | Kao Corporation | Agent for preventing or ameliorating obesity |
| CN104621469A (en) * | 2015-01-14 | 2015-05-20 | 魏永义 | Food with function of reducing blood pressure |
| CN105918778A (en) * | 2016-04-25 | 2016-09-07 | 江苏强农农业技术服务有限公司 | Health-care seaweed extract medicinal granules capable of beautifying features and reducing blood lipid |
| CN107126439A (en) * | 2017-04-24 | 2017-09-05 | 上海陶盛生物技术有限公司 | Carboxymethyl chitosan is being prepared or screened for the purposes in antihypertensive product |
| CN114685320A (en) * | 2020-12-31 | 2022-07-01 | 武汉远大弘元股份有限公司 | Gaminobutylamine taurate and preparation method and application thereof |
-
2008
- 2008-06-06 CN CN2008100286200A patent/CN101306011B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283338B2 (en) | 2007-11-30 | 2012-10-09 | Kao Corporation | GIP secretion inhibitor |
| US8338389B2 (en) | 2009-06-17 | 2012-12-25 | Kao Corporation | Agent for preventing or ameliorating obesity |
| CN104621469A (en) * | 2015-01-14 | 2015-05-20 | 魏永义 | Food with function of reducing blood pressure |
| CN105918778A (en) * | 2016-04-25 | 2016-09-07 | 江苏强农农业技术服务有限公司 | Health-care seaweed extract medicinal granules capable of beautifying features and reducing blood lipid |
| CN107126439A (en) * | 2017-04-24 | 2017-09-05 | 上海陶盛生物技术有限公司 | Carboxymethyl chitosan is being prepared or screened for the purposes in antihypertensive product |
| CN114685320A (en) * | 2020-12-31 | 2022-07-01 | 武汉远大弘元股份有限公司 | Gaminobutylamine taurate and preparation method and application thereof |
| CN114685320B (en) * | 2020-12-31 | 2024-04-09 | 武汉远大弘元股份有限公司 | Agmatine taurine salt and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101306011B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101306011B (en) | Function food for synthetically reducing blood pressure | |
| CN103609944B (en) | Blood pressure reducing and sleeping promoting health-care food | |
| CN103054044B (en) | Sleep-improving health food composition | |
| JP2012197283A (en) | Treatment using citrulline | |
| US20150056297A1 (en) | Nutraceutical combination for prevention and treatment of type 2 diabetes | |
| CN1970007A (en) | Capsule for improving sexual function for men | |
| CN103997914A (en) | Dietary product intended for the prevention of cardio-metabolic risk | |
| KR102348361B1 (en) | Composition for promoting differentiation of muscle cells containing amino acids | |
| EP3452012A1 (en) | Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto | |
| CN101766715B (en) | Composite for disintoxicating and sobering | |
| CN101766672B (en) | Composition for anti-alcohol and sobering | |
| CN103222621B (en) | Body benefiting and oxidation resisting healthcare product | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| KR20140017977A (en) | Vita hybrid tablet for senior and manufacturing method thereof | |
| CN104783033A (en) | Oyster deep-processing composite functional food | |
| CN101306009A (en) | Function food for protecting nourishing the liver | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| CN105166901B (en) | A kind of dialysis patient alimentation composition | |
| CN102228620B (en) | Chinese medicinal compound preparation having the functions of supplementing iron and enriching the blood and preparation method thereof | |
| CN101306010B (en) | Function food for reducing the blood sugar and preventing diabetes complicating disease | |
| CN101336723A (en) | Health food for relieving physical fatigue | |
| CN109953347A (en) | A kind of collagen protein powder improving person in middle and old age's memory | |
| CN110122809A (en) | A kind of diabetes nutritive yam reinforcing powder | |
| CN105286020B (en) | A kind of nontransparent PCI-PCI bridge alimentation composition | |
| KR20160068238A (en) | Composition for preventing or improving metabolic syndrome containing panasenoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20200606 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |